336 related articles for article (PubMed ID: 3841156)
1. Differential ontogeny of putative M1 and M2 muscarinic receptor binding sites in the murine cerebral cortex and heart.
Evans RA; Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1985 Dec; 235(3):612-8. PubMed ID: 3841156
[TBL] [Abstract][Full Text] [Related]
2. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes.
Watson M; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1986 May; 237(2):419-27. PubMed ID: 3754581
[TBL] [Abstract][Full Text] [Related]
3. [3H]pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. I. Characterization and regulation of agonist binding to putative muscarinic subtypes.
Watson M; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1986 May; 237(2):411-8. PubMed ID: 3754580
[TBL] [Abstract][Full Text] [Related]
4. Muscarinic cholinergic receptor binding sites differentiated by their affinity for pirenzepine do not interconvert.
Gil DW; Wolfe BB
J Pharmacol Exp Ther; 1986 May; 237(2):577-82. PubMed ID: 3009794
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to a synthetic peptide can be used to distinguish between muscarinic acetylcholine receptor binding sites in brain and heart.
Luthin GR; Harkness J; Artymyshyn RP; Wolfe BB
Mol Pharmacol; 1988 Sep; 34(3):327-33. PubMed ID: 3419425
[TBL] [Abstract][Full Text] [Related]
6. Comparison of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to muscarinic cholinergic receptors in rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1984 Mar; 228(3):648-55. PubMed ID: 6546770
[TBL] [Abstract][Full Text] [Related]
7. Characterization of [3H]pirenzepine binding to muscarinic cholinergic receptors solubilized from rat brain.
Luthin GR; Wolfe BB
J Pharmacol Exp Ther; 1985 Jul; 234(1):37-44. PubMed ID: 3839265
[TBL] [Abstract][Full Text] [Related]
8. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes.
Burke RE
Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217
[TBL] [Abstract][Full Text] [Related]
9. Regulation of muscarinic receptor subtypes and their responsiveness in rat brain following chronic atropine administration.
Lee W; Wolfe BB
Mol Pharmacol; 1989 Nov; 36(5):749-57. PubMed ID: 2555673
[TBL] [Abstract][Full Text] [Related]
10. Irreversible and quaternary muscarinic antagonists discriminate multiple muscarinic receptor binding sites in rat brain.
Norman AB; Eubanks JH; Creese I
J Pharmacol Exp Ther; 1989 Mar; 248(3):1116-22. PubMed ID: 2703964
[TBL] [Abstract][Full Text] [Related]
11. A unique regulatory profile and regional distribution of [3H]pirenzepine binding in the rat provide evidence for distinct M1 and M2 muscarinic receptor subtypes.
Watson M; Yamamura HI; Roeske WR
Life Sci; 1983 Jun; 32(26):3001-11. PubMed ID: 6688111
[TBL] [Abstract][Full Text] [Related]
12. Cholinergic innervation and topographical organization of muscarinic binding sites in rat brain: a comparative autoradiographic study.
Tonnaer JA; Ernste BH; Wester J; Kelder K
J Chem Neuroanat; 1988; 1(2):95-110. PubMed ID: 3267343
[TBL] [Abstract][Full Text] [Related]
13. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain.
Norman AB; Creese I
Mol Pharmacol; 1986 Aug; 30(2):96-103. PubMed ID: 3755499
[TBL] [Abstract][Full Text] [Related]
14. Muscarinic receptor subtypes in human nasal mucosa: characterization, autoradiographic localization, and function in vitro.
Okayama M; Mullol J; Baraniuk JN; Hausfeld JN; Feldman B; Merida M; Shelhamer JH; Kaliner MA
Am J Respir Cell Mol Biol; 1993 Feb; 8(2):176-87. PubMed ID: 8427708
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological differences between the high-affinity muscarinic agonist binding states of the rat heart and cerebral cortex labeled with (+)-[3H]cismethyldioxolane.
Vickroy TW; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1984 Jun; 229(3):747-55. PubMed ID: 6202869
[TBL] [Abstract][Full Text] [Related]
16. On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors.
Nilvebrant L
Acta Pharmacol Toxicol (Copenh); 1986; 59 Suppl 1():1-45. PubMed ID: 3524114
[TBL] [Abstract][Full Text] [Related]
17. Solubilization with digitonin alters the kinetics of pirenzepine binding to muscarinic receptors from rat forebrain and heart.
Wang JX; Mei L; Yamamura HI; Roeske WR
J Pharmacol Exp Ther; 1987 Sep; 242(3):981-90. PubMed ID: 3116203
[TBL] [Abstract][Full Text] [Related]
18. [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization.
Luthin GR; Wolfe BB
Mol Pharmacol; 1984 Sep; 26(2):164-9. PubMed ID: 6548291
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic characterization of muscarinic receptors of insect brains.
Abdallah EA; Eldefrawi ME; Eldefrawi AT
Arch Insect Biochem Physiol; 1991; 17(2-3):107-18. PubMed ID: 1802028
[TBL] [Abstract][Full Text] [Related]
20. Characterization of high affinity [3H]pirenzepine and (-)-[3H] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in rabbit peripheral lung.
Bloom JW; Halonen M; Lawrence LJ; Rould E; Seaver NA; Yamamura HI
J Pharmacol Exp Ther; 1987 Jan; 240(1):51-8. PubMed ID: 3806397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
